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Abstract Luteolin (30,40,5,7-tetrahydroxyflavone) is a
common flavonoid in many types of plants and has several
beneficial biological effects, including anti-inflammation,
anti-oxidant, and anti-cancer properties. However, the
detail mechanisms of luteolin in suppressing tumor inva-
sion and metastasis are poorly understood. Here, we
investigated the effects of luteolin on suppressing glio-
blastoma tumor cell invasion and migration activity. Under
the non-cytotoxic doses (15 and 30 lM), luteolin exhibited
an inhibitory effect on migration and invasion in U-87 MG
and T98G glioblastoma cells. Additionally, filopodia
assembly in U-87 MG cells was markedly suppressed after
luteolin treatment. The treatment of luteolin also showed a
decrease of Cdc42 (cell division cycle 42) protein levels
and reduced PI3K/AKT activation, whereas there was no
association between this decrease and phosphorylated ERK
or altered transcription levels of Cdc42. Over expression of
constitutive Cdc42 (Q61L) using transient transfection in
U-87 MG cells induced a partial cell migration, but did not
affected the degradation of the protein levels of Cdc42 after
luteolin treatment. Moreover, inhibition of the proteaosome
pathway by MG132 caused a significant recovery in the
migration ability of U-87 MG cells and augmented the
Cdc42 protein levels after luteolin treatment, suggesting
that pharmacological inhibition of migration via luteolin
treatment is likely to preferentially facilitate the protein
degradation of Cdc42. Taken together, the study demon-
strated that flavonoids of luteolin prevent the migration of
glioblastoma cells by affecting PI3K/AKT activation,
modulating the protein expression of Cdc42 and facilitating
their degradation via the proteaosome pathway.
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Introduction
Glioblastoma multiforme (GBM), the most common and
most aggressive primary brain tumor, is a highly malignant
lesion with poor prognosis. The standard therapeutic
strategy for GBM is multimodality treatment, including
surgical resection and postoperative radiotherapy combined
with chemotherapy. Whereas, more than 70 % of GBM
patients die within 2 years of diagnosis [1]. In high-grade
glioma, the results of contemporary drug treatments are not
satisfactory. Fatal GBMs are characterized by rapid cell
proliferation and aggressive invasion and destroy of the
surrounding normal brain tissue.
Luteolin is one of the most common flavonoids presents
in edible plants and in plants are used to treat a wide
variety of pathologies by traditional medicine. The poten-
tial benefits of luteolin (50 mg/kg body weight) in CNS
include decreased inflammation and axonal damage by
preventing monocyte migration across the blood–brain
barrier (BBB) [2]. Preclinical studies have shown that this
flavones possesses a variety of pharmacological activities,
including anti-inflammation, anti-oxidation, anti-prolifera-
tion anti-angiogenesis, and anti-metastasis [2–13]. In
prostate cancer, the investigators found that luteolin sup-
pressed proliferation and induced apoptosis in vitro and
in vivo via inhibition of the IGF/1R/AKT signaling path-
way [14]. Bagli et al. [15] have proved that luteolin
inhibited tumor growth and angiogenesis in a murine
xenograft model and decreased vascular endothelial growth
factor (VEGF)-induced in vivo angiogenesis via inhibition
of the phosphatidylinositol 30-kinase (PI3K) pathway.
Other reports show that luteolin inhibits and poisons topo I
and II in leukemia cells [16] and Chinese hamster ovary
AA8 cells [17]. The activity of luteolin on topoisomerases I
and II may has therapeutic implications, as these enzymes
are the target of several drugs such as etoposide, topoteca,
irinotecan, commonly used in the treatment of cancer.
However, another evidence suggest that luteolin may pre-
vent these processes by inhibiting matrix metalloprotein-
ases (MMPs) and focal adhesion kinase (FAK) [18].
Luteolin plays an anti-tumorigenic role in various cancers
through inhibiting carcinogen activation, suppressing cell
growth, inducing cell apoptosis and inhibiting metastasis
[19]. However, the detail mechanisms of luteolin-mediated
inhibition of glioblastoma cell migration are, yet, unclear.
The Ras-ERK1/2 MAP kinase pathway plays a critical
role in numerous cellular processes, including prolifera-
tion, differentiation, survival, and motility [20]. Growth
factors activate ERK-MAPK by signaling through their
cognate receptors at the cell surface to the small GTPase
Ras. ERK activity may also be induced via ECM signaling
during adhesion. In this pathway, the small GTPases Rac
and cell division cycle 42 (Cdc42) activate PAK (p21-
activated kinase), which phosphorylates MEK to make it a
more efficient Raf substrate [21]. Whereas at Rho family
gene, Cdc42 is an important for cell motility and able to
induce a mesenchymal-amoeboid transition in melanoma
cells [22]. Cdc42 GTPase is a key signaling component
governing actin cytoskeleton organization, adhesion,
migration, proliferation, and survival in mammalian cells
[23]. Active forms of Rac1 and Cdc42 regulated the
direction of cell movement and have a positive effect on
E-cadherin mediated cell–cell adhesions which increased
number of filopodia, actin reach finger-like protrusions
[24]. By inhibiting the activation of Cdc42 showed the
importance in reducing motility and invasion in glioma
cells.
In this study, we proved that luteolin inhibited the
migratory and invasion in human glioblastoma U-87 MG
and T98G cells. The migration property of luteolin-medi-
ated inhibition was exerted via inhibition of phosphorated
PI3K/AKT and resulted in rapid Cdc42 proteolysis.
Materials and methods
Chemicals
Luteolin ([98 % purified) was obtained from Cayman
Chemical Company (Cat 10004161). Stock solutions of
luteolin were prepared in DMSO and stored at -20 C.
Cycloeximide (CHX) (#C4859) and MG132 (Z-Leu-Leu–
Leu-al) (#C2211) from Sigma-Aldrich (USA). Subsequent
dilutions were made in Dulbecco’s modified Eagle’s
medium (DMEM).
Cell culture and transfection
Human glioblastoma cell line (U-87 MG and T98G), and
HUVECs used in this study was obtained from the Amer-
ican type culture collection (ATCC, Manassas, VA). U-87
MG and T98G cells were maintained in monolayer culture
in DMEM (GIBCO, Rockville, MD, USA), containing
10 % fetal bovine serum (FBS) (Hyclone, Logan, UT), 100
lg/ml penicillin and 100 lg/ml streptomycin (Gibco BRL,
Rockville, MD) at 37 C in a humidified atmosphere
comprising of 95 % air and 5 % CO2. HUVECs grown in
Clonetics Endothelial Cell Growth Medium-2 (EGM-2;
Lonza, Walkersville, MD). Transient transfected U-87 MG
cells were generated by transfection with 1 lg of pEGFP-
C1 or pcDNA3-EGFP-Cdc42-Q61L (purchased from
Addgen: plasmid 12986) using jetPEI (Polyplus-transfec-
tion, 101-10) and incubated for 48 h. The medium was
removed and fresh medium containing 30 lM of luteolin
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was added to the wells, then treated continuously with
luteolin for 24 h.
Cell viability assay
Cells were seeded in 96-well plates at a density of 1 9 104
per well for 24 h and then treated with various concen-
trations of luteolin (dissolved in 0.1 % dimethyl sulfoxide
(DMSO and diluted with DMEM medium with 4 % FBS to
10, 20, 30, 40, 50 lM) for 24 h. The DMSO in culture
medium did not exceed 0.1 %, a concentration known not
to affect cell viability. Cell viability was determined by
3-(4,5-dimethylthiazol-2-yl)-5-(3-Carboxymethoxyphenol)-2-
(4-Sulfophenyl)-2H-tetrazolium, inner salt (MTS) method,
following the manual of Cell Titer 96 Aqueous One
Solution Cell viability assay (Promega, Cat.#: G3582). The
cell viability in each group was determined by absorbance
under an optical density value of 490 nm (450–540 nm)
with a 96-well plate reader.
Wound healing assay
In a 24-well plate, U-87 MG and T98G cells were added to
high glucose DMEM media, and incubated for 24 h in
order to create a monolayer of cells. A scratch was made in
the middle of the well with a P200 pipette tip. The debris
was washed away and new media was added to the wells.
Under the micro-scope, the cells were imaged and the
initial area of the scratch for the field of view was deter-
mined by multiplying the length by the average width of
the area devoid of cells. The plate was incubated at 37 C
for 12 h, after which the same field of view was imaged
and the area devoid of cells was recalculated by the same
method.
Invasion and migration assay
The invasion assay was performed by using 24-well BD
Biocoat Matrigel invasion chambers with 8 lm polycar-
bonated filters (Becton–Dickinson, Bedford, MA). U-87
MG cells were seeded on Matrigel invasion chamber
plates, and cultured in routine medium. Cells were incu-
bated for 24 h at 37 C in a humidified incubator with 5 %
CO2. Nonmigratory cells on the upper surface of the filter
were removed by wiping with a cotton swab. Invasive cells
that penetrated through pores and migrated to the underside
of the membrane were stained with Giemsa solution after
fixation with 4 % formaldehyde in PBS. The cell number
was counted under microscopic vision, and the average cell
number was determined. The migration assay was similar
to invasion assay. Overall, the migration assay is similar
to the invasion assay except for that it does not contain
Matrigel chambers.
RT-PCR assay
The expression of Cdc42 gene was quantified by reverse
transcriptase PCR. Total RNA was prepared from the cell
line using RNeasy Mini kit (Qiagen, Inc.) For cDNA
preparation, 1 mg of total RNA was retro transcribed by
High-Capacity cDNA Archive Kit (Applied Biosystems,
Foster City, CA, USA) at 37 C for 2 h. PCR amplification
was performed in a 50 ll reaction volume containing 1 lg
cDNA reaction and using ampliTaq Gold polymerase
(Perkin Elmer). The primer sequences used for each PCR
are outlined below. Primer sequences for Cdc42 were (F):
50-TATGATTGGTGGAGAACCAT-30 and (R): 50-ATT-
CTTTAGGCCTTTCTGTG-30 (Genbank accession no.
M57298, resulting in a 370 bp PCR product).
Western blot analysis
Cells were lysed in lysis buffer containing 50 mM Tris–
HCl, pH 7.5, 150 mM NaCl, 1 % Nonidet P-40, 0.25 %
sodium dexycholate, 0.1 % SDS with complete protease
inhibitor cocktail (Roche, 04693159001) and protein con-
centration was assayed with Bio-Rad Protein Assay Kit
(Bio-Rad, 500-0006). Equal amounts of proteins from each
sample were separated by sodium dodecyl sulfate (SDS)
polyacrylamide gel electrophoresis and transferred to
polyvinylidene difluoride membrane (PVDF) (Amersham,
RPN303F). Membrane was blocked for 1 h in TBS con-
taining 5 % non fat milk and 0.2 % Tween 20. For the
detection of ERK, phospho-ERK, Cdc42, Rac1 and GAP-
DH. For the detection of antibodies : ERK (Santa Cruz, sc-
93), phospho-ERK (Santa Cruz, sc-7383), phospho-PI3
kinase p85 (Cell Signaling, #4228), phospho-SAPK/JNK
(Cell Signaling, #4668), phosphor-p38 (Cell Signaling,
#4511), F-actin (Novus, NB100-64792), Cdc42 (Santa
Cruz, sc-8401), Rac1 (Santa Cruz, sc-95), anti-GFP
(Novus, SP3005P), phosphor-AKT (pS473) (Epitomics,
#2118), AKT (Epitomics, #1080), phosphor-FAK (Novus,
NB100-92712) and GAPDH (Santa Cruz, sc-25778), these
primary antibodies were incubated with membranes at 4 C
overnight. Finally, the membranes were incubated with
horseradish peroxidase-conjugated secondary antibody and
developed using ECL Western blot reagents (PerkinElmer,
nel104).
Phalloidin stain of filopodia
Filopodia of U-87 MG cells were detected using fluores-
cent phalloidin and analyzed by confocal microscopy. Cells
were seeded to the glass cover slips in cell dishes (24 well
plate) overnight. Luteolin was then added and cells were
cultured for 24 h. After fixing with 4 % paraformaldehyde,
cells were treated with 0.1 % Triton X-100 for 20 min and
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blocked with 3 % BSA for 30 min. Then cells were incu-
bated with 100 nM Rhodamine-conjugated phalloidin for
30 min and examined under confocal laser scanning
microscope (12009 oil). The results were repeated at three
independent experiments in each case.
Statistical 1analysis
Multiple samples were collected in each measurement and
expressed as mean ± standard deviation. Single-factor
analysis of variance (ANOVA) method was used to assess
the statistical significance of the results. p values \ 0.05 or
0.01 were considered statistically significant.
Results
Effects of luteolin treatment in U-87 MG and T98G
glioblastoma cells
We investigated whether luteolin administration increases
the cellular cytotoxicity and to look for the appropriate
concentration of luteolin for further study in the possible
novel physiological effects. U-87 MG and T98G glioblas-
toma cells were treated with various concentrations (0, 10,
20, 30, 40 and 50 lM) of luteolin for 24 h and examined the
effects of luteolin on different glioblastoma cell lines were
examined with MTS assay. As shown in Fig. 1, the cell
viability was no significant decreased at conc. up to 20 lM
of luteolin, even conc. up to 30 lM of luteolin (retained
86.8 % of viability cells). However, the declines of the U-87
MG cell population might represent the increases of dead
cells when the concentration of luteolin is more than 40 lM
(23.1 %) (Fig. 1a). Similar cytotoxicity effects of luteolin
were observed in T98G cells (Fig. 1b). In addition, we
showed that in addition to no inhibiting growth of the
glioblastoma cells, luteolin (30 lM) decreased cancer cell
migration but do not affect normal cell growth (human
umbilical vein endothelial cell, HUVECs) (Fig. 1c). There-
fore, to exclude the cytotoxic effects of excess luteolin, the
following experiment would to use 30 lM of luteolin to
determine the related effects on U-87 MG and T98G cells.
Luteolin inhibits migration and invasion in U-87 MG
and T98G cells
GBM patients dies more often from invasion and migra-
tion, therefore cell migration is a key feature of tumor
progression and malignant. To investigate the anti-migra-
tory effects of luteolin, U-87 MG cells were examined
using wound healing assay. The monolayer of U-87 MG
and T98G cells was scratched with a pipette tip and treated
with moderated concentrations of luteolin (0, 15, and
30 lM) for 24 h. As shown in Fig. 2a, b, there is a sig-
nificant drop in the ability of the luteolin 30 and 15 lM
treated cells to migrate into the empty space compared with
Fig. 1 Effect of luteolin in
U-87 MG and T98G cells
viability. a U-87 MG cells and
b T98G cells were seeded in
96-well plates at a density of
1 9 104 per well and incubation
O/N, and then treated with
various concentrations (0, 10,
20, 30, 40 and 50 lM) of
luteolin for 24 h. Cell viability
was measured by MTS assay.
Values are the mean ± SEM
results from three independent
experiments. *p \ 0.05.
c Effect of luteolin (30 lM) on
HUVECs viability in culture
after the treatment with DOSM
(left panel) or luteolin for 24 h.
Cell death of the HUEVCs was
observed by light microscopy.
Scale bars 50 lm
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vehicle control in U-87 MG and T98G cells (Fig. 2c, d).
The Boyden chamber assay, originally introduced by
Boyden for the analysis of leukocyte chemotaxis, is based
on a chamber of two medium-filled compartments sepa-
rated by a microporous membrane. We therefore deter-
mined the effect of luteolin on cellular migration in U-87
MG glioblastoma cells. As shown in Fig. 2e, U-87 MG
cells treatment with luteolin resulted in a significantly
inhibition of cell migration, as well as shown in Fig. 2f
present at 15 lM (45.9 %) and 30 lM (31.2 %) under
luteolin treatment. To further determine the effects of
luteolin on the cell invasive properties of the previously
established cell models, using penetration through addition
of MatrigelTM in above method as measured invasion
ability. U-87 MG cells was performed for evaluating the
ability of cellular invasion. As shown in Fig. 2g, the
number of cells crossed Matrigel in the luteolin treatment
was significant decreased compared to the control cells, as
shown in Fig. 2h, U-87 MG cells was slightly decreased at
luteolin at 15 lM (87.2 %) and 30 lM (67.3 %), respec-
tively. These results suggested that although luteolin
(30 lM) treatment did not significantly affect the cellular
viability, the luteolin inhibited the cell migration and
invasion in U-87 MG and T98G cells.
Luteolin inhibits migration of glioma cells through
down-regulation of Cdc42 expression
We sought to investigate the cause of the inhibition of cell
migration upon luteolin treatment in U-87 MG cells. We
noted that ERK1/2 was inactivated using the MEK inhibitor,
U0126, the cell migration was significantly inhibited
(Fig. 3a) as previously study [25]. The cell migration in the
luteolin treatment of U-87 MG cells was significantly
inhibited using Boyden chamber assay detection (Fig. 3a).
The quantification of migratory ability of U-87 MG cells
treated with U0126 or luteolin was significant decreased to
37.5 and 31.5 %, respectively. (Fig. 3b). Therefore, to
examine the change in the activation of ERK and other key
regulatory pathways signal pathway after the luteolin treat-
ment, whole cell lysate of U-87 MG cells after treatment
with luteolin for 24 h were analyzed for protein expression
of phosphor-ERK, total ERK, using Western Blotting assay.
As shown in Fig. 3c, the protein expressions of phosphor-
ylated ERK1/2 (p-ERK) were significantly reduced after
U0126 treatment. However, the protein expression of p-ERK
was not significantly affected by luteolin, and the expression
of total ERK also remained consistent, indicating that there
was no association between luteolin treatment and any
inhibition of migration ability in the active ERK pathway.
Remarkably, both PI3 K and AKT activations were partially
reduced in the intensity of phosphorylation protein after
luteolin treatment, whereas other key regulatory pathways,
such as p38, FAK and JNK, did not affected, suggesting that
luteolin could reduced PI3K/AKT activation in glioblastoma
cells (Fig. 3c). To evaluated the function effect of combi-
nation of U0126 and luteolin to inhibit cell migration, we
performed the wound-healing assay in U-87 MG cells. As
shown in Fig. 3d, the single treatment of U0126 or luteolin
have a significantly similar inhibitory of migration, and
cotreatment showed a synergy inhibitory effect of migration
in U-87 MG cells (Fig. 3e). In addition, we also examined
the cellular cytotoxicity of U0126 at 30 lL concentration
and did not significantly affected in the growth of U-87 MG
cells (Fig. 3f). Taken together, these data indicate that the
inhibitory of migration in luteolin is likely mediated through
impaction on PI3K/AKT activation.
Several studies have shown that actin polymerization,
which leads to filopodia assembly and depolymerization,
play a crucial role in cell motility [26, 27]. We attempted to
explore the molecular events in response to treatment with
luteolin, the formation of the actin cytoskeleton in U-87
MG cell was assessed by staining with Rhodamine-phal-
loidin, which specifically binded F-actin [28]. The results
showed that filopodia assembly in U-87 MG was abolished
by luteolin (30 lM) (Fig. 4a). Therefore, luteolin sup-
pressed the migration of U-87 MG at least in part dis-
rupting actin assembly and filopodia formation.
Cell division cycle 42 signaling is essential for cell
motility and is related to filopodia formation. To further
explore luteolin effects on the cell cytoskeleton with regard
to oncogenic transformation, we examined the protein
expression levels of Cdc42 in U-87 MG and T98G cells.
This analysis indicated that added luteolin (30 lM) atten-
uated the protein levels of Cdc42 in U-87 MG and T98G
cells as well as the expression of the F-actin protein
(Fig. 4b). The protein expression levels of Cdc42 exhibited
at a dose-dependent decrease upon luteolin treatment,
whereas the protein levels of Rac1 were decreased to a
lesser extent (Fig. 4c). Notably, the mRNA levels of Cdc42
were not impacted after luteolin treatment of U-87 MG
cells (Fig. 4d), suggesting that there was no association
between the decrease of Cdc42 protein levels and the levels
of mRNA transcription.
To determine whether the effect of luteolin reduced the
half-life of Cdc42 protein, we examined effects of cyclo-
heximide (CHX), a protein synthesis inhibitor. U-87 MG
cells were treated with 50 lg/ml CHX to block new protein
synthesis. Cdc42 proteins in the present of luteolin showed
more rapid degradation kinetics compared to the control
treatment (Fig. 4e). The half-life of Cdc42 in the present of
luteolin was approximately 24 h, whereas the half-life of
co-treatment with luteolin and CHX has been reduced to
less than 8 h (Fig. 4e). These results demonstrated that
luteolin resulted in rapid Cdc42 proteolysis in glioblastoma
cells.
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To explore the importance of Cdc42 activation in the
induced cell migration observed, transient transfection of
constitutive active Cdc42 (EGFP-Cdc42-Q61L) in U-87
MG cells was performed (Fig. 5a). Significant green fluo-
rescence was observed in U-87 MG cells (approximately
30–35 % of total cells; Fig. 5a). Subsequent analysis of the
Fig. 2 Luteolin inhibited migration and invasion of U-87 MG and
T98G cells. Wound healing assay was performed on a U-87 MG cells
and b T98G cells. Cells (1.2 9 105 cells/24 well) were treated with
luteolin (0, 15, and 30 lM) for 24 h. The plates were photographed at
0 and 24 h post-wounding. The cells migrating into the wound area
were counted based on the dashed line as time zero. c, d The
quantification analysis of above wounds healing quantification. Data
are expressed as the mean ± SE from three independent experiments.
*p \ 0.05. **p \ 0.01. e Boyden chamber for evaluation of migra-
tion in U-87 MG cells treated with luteolin. f Quantification of
migration in Boyden chamber. g Invasion chamber assay for
evaluating the invasion rate of U-87 MG cells treated with luteolin.
The bottom chamber was filled with DMEM medium. The upper
chambers of membrane were coated with 3 lg of Matrigel. After
luteolin treatment for 24 h, the invading U-87 MG cells passed
through the membrane and were quantified by counting the cells that
migrated onto the membrane. Cells were fixed, stained, and counted
as described in the text. h Quantification of invasion in Invasion
chamber system. Invasion rate of 100 % is defined by control group
which contained invasive U-87 MG cells without treatment of
luteolin. The data are presented the as mean ± SD results from
triplicate independent experiments. Indicates significantly difference
from vehicle of U-87 MG and *p \ 0.05
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wound healing properties showed that moderate Cdc42
activation increased a partial cell migration response upon
luteolin treatment (Fig. 5b, c). Notably, the protein levels
of Cdc42 were substantially impaired both exogenously
and endogenously after luteolin treatment (Fig. 5d), further
illustrating that the mechanism of luteolin in inhibiting
migration potentially facilitated the degradation of the
Cdc42 protein levels.
To determine whether the inhibitory effect of luteolin on
migration in U-87 MG cells was dependent on proteosome
degradation of Cdc42, we examined the single and com-
bined effects of luteolin and MG132, a proteasome inhib-
itor, on U-87 MG cells. As shown in Fig. 6a, following the
addition in combination of MG132 (0.125 lM) and luteo-
lin at 4 h before analysis, the number of moving cells were
noticeably increased as compared to luteolin only treatment
(Fig. 6b), whereas MG132 did not affect the ability of U-87
MG cells to migrate compared to control in vitro. More
specifically, MG132 provided a prevention to against the
degradation of Cdc42 by luteolin treatment in U-87 MG
Fig. 3 Luteolin and U0126 inhibited the migration of U-87 MG cells.
a Boyden chamber assay for evaluation of migration in glioma cells
treated with luteolin (30 lM) or specific ERK inhibitor U0126
(30 lM) for 24 h. b Quantification of migration was modified by
Boyden chamber assay. Scale bars are 50 lm. Data were expressed as
the mean ± SE from three independent experiments. **p \ 0.001.
c U-87 MG and T98G cells were treated for 24 h with luteolin
(30 lM), followed by western blot analysis for phosphorylated ERK
(p-ERK), total ERK, p-PI3 K, p-JNK, p-p38, p-AKT, total AKT and
FAK. GAPDH was a loading control. These results are representative
of three independent experiments. d Wound healing assay was
performed on U-87 MG cells. Luteolin (L) (30 lM) with or without
10 lM U0126 (U) were added. Migrated cells were quantified by
manual counting. e The above data were presented the quantification
analysis of above wounds healing quantification. Data are expressed
as the mean ± SE from three independent experiments. **p \ 0.01
compared with control group. f Light-microscopy of U-87 MG cells
were treated without/with U0126 (30 lM) for 24 h
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cells, some similar to control group (Fig. 6c). Thus, the
inhibition of migration resulting from the pharmacological
mechanism of luteolin is likely to facilitate the protein
degradation of Cdc42 by activation of the proteosome
degradation pathway.
Discussion
In this study, we have shown that luteolin at non-toxic
contractions is a potent modulator of migration and inva-
sion of U-87 MG and T98G glioblastoma cells. However,
we found that luteolin treatment did not interrupt the
phosphorylation of ERK as well as affected to a lesser
extent on other key regulatory pathway such as MAPK-
p38, FAK, and JNK, whereas possible due to luteolin
produced the reduction of PI3K/AKT activation. In addi-
tionally, we clearly showed that luteolin disrupted cell
migration at least in part through preventing filopodia
formation and Cdc42 protein levels after luteolin treatment.
Transient transfection of constitutive active Cdc42 (EGFP-
Cdc42-Q61L) in U-87 MG cells increased the partially
ability of migration in the present of luteolin, but did not
affect the degradation levels of Cdc42 protein. Finally, we
found that luteolin facilitated a significant protein degra-
dation of Cdc42 via the proteaosome-dependent degrada-
tion pathway. Collectively, luteolin treatment inhibited the
activation of PI3K and thereby suppressed the AKT med-
iated migration signal pathways, and resulted in rapid
Cdc42 proteolysis.
Cell migration events are determined largely by cyto-
skeleton, the internal scaffolding of proteins that give cell
shape, polarity and the capacity to move. Inhibition of
U-87 MG and T98G cell motility by luteolin was con-
firmed by wound healing (Fig. 2a, b, c, d) and modified
Boyden chamber assay (Fig. 2e, f, g, d). However, luteolin
has no cytotoxic effect on glioma cells at concentrations
below 30 lM (Fig. 1). Therefore, we suggested the
blockade of migration by luteolin is not through its cyto-
toxic effects. ERK 1/2 and MAPK subfamily promote the
proliferation and motility of cells. Rac1 and Cdc42, which
lead to form membrane ruffles/lamellipodia and filopodia
respectively, have been shown to regulate a vast spectrum
of biological functions, including cell cytoskeleton func-
tion and cell polarity during migration [24, 29]. The effects
of Cdc42, Rac1 and Rho on the cytoskeleton and cellular
adhesion suggest a possible role for Rho proteins in cellular
migration [30, 31]. The decrease of Cdc42 and Rac1 may
Fig. 4 Luteolin disrupts actin
assembly and filopodia
formation. a Glioblastoma cells




detects F-actin. In the control,
filopodia are present (white
arrow, left). Incubation of U-87
MG cells with luteolin (30 lM)
for 24 h led to marked
disruption of filopodia assembly
(right). Scare bars are 20 lm.
b U-87 MG and T98G cells
were treated with luteolin
(30 lm) for 24 h, followed by
western blot analysis for Cdc42
and F-actin. GAPDH was a
loading control. c U-87 MG
cells were treated with 0, 10, 20,
30 lm concentration of luteolin
for 24 h, followed by western
blot analysis for Cdc42 and
Rac1. b-actin was a loading
control. d Total mRNA were
concentrated in U-87 MG cell
after luteolin (0, 10, 20 and
30 lM) for 24 h and gene
expression levels of Cdc42 were
assessed by RT-PCR
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involve in the blocking of cell migration. We found that
luteolin inhibited the cell migration of glioblastoma and
managed to decrease the protein expression of Cdc42 and
F-actin (Fig. 4b). We also observed that luteolin inhibited
U-87 MG cell morphology (less spread) using Boyden
chamber assay (Fig. 2e, g). The morphology of U-87 MG
cells was in response to Cdc42 and Rac1 activity by lute-
olin treatment.
Fig. 5 Effect of transfected constitutive active Cdc42 (Q61L) in
U-87 MG cells upon luteolin treatment. a phenotypes of U-87 MG
cells transfected with EGFP fused to constitutive active mutant of
Cdc42 (Q61L) (green flurescence) and merged with phase image; bar
represents 100 lm. b Wound healing assay was performed on U-87
MG cells after transfected with EGFP or EGFP-Cdc42 (Q61L).
Luteolin (30 lM) were added to U-87 MG cells. Migrated cells were
quantified by manual counting. c The above data were presented the
quantification analysis of above wounds healing quantification. Data
are expressed as the mean ± SE from three independent experiments.
*p \ 0.05 compared with luteolin group of transfected with EGFP
control plasmid DNA. d After transfected with EGFP or EGFP-Cdc42
(Q61L), U-87 MG cells were treated with luteolin (30 lL) for 24 h,
followed by western blot analysis for anti-Cdc42 and anti-GFP.
GAPDH was a loading control
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It is known that the increase in ERK signaling might be
highly correlated with GBM proliferation [32] and tumor
metastasis. However, the prevention of tumor invasion/
migration is one of the goals for glioma patients. The
migratory process requires the coordinated activation and
targeting of both structural and signaling molecules [33].
Increased expression of ERK signaling might contribute to
GBM proliferation [32]. Cytoskeleton changing regulated
by Rac1 and Cdc42 correlated with MAPK/ERK signaling
pathway may serve critical molecular signaling in the
development of cell mobility [30, 34]. Previous studies
demonstrated that luteolin inhibited inflammatory respon-
ses and down-regulation of ERK signal transduction
pathway in human colon epithelial cells and migration of
F9 parietal endoderm cells was regulated by the ERK
pathway [35]. In our study, luteolin was not affected the
phosphorylated ERK as well as other key regulatory
pathways such as MAPK-p38, JNK, and FAK (Fig. 3c).
However, luteolin showed a particularly inhibitory effect
on PI3K and AKT activation, which functional mediator in
cell migration [36]. The inhibitory effect of luteolin on
PI3K/AKT activity can vary depending on the cellular
context. In addition, AKT is downstream serine/threonine
kinase in the RTK/PTEN/PI3K pathway and large scale
genomic analysis of GBM has demonstrated that this
pathway is mutated in the majority of GBMs. This RTK/
PTEN/PI3K pathway leads to activated AKT and phos-
phor-AKT levels are elevated in the majority of GBM
tumor samples and cell lines, which studies show help
glioma cells grow uncontrolled, evade apoptosis, and
enhance tumor migration and invasion. Thus, luteolin tar-
geting the inhibitory of AKT activation represent a
potential treatment option against GBM and additional
research efforts are required to fully explore and develop
this possible treatment strategy.
Although in recent years, the anti-tumorigenic role of
luteolin has been well recognized, the role of luteolin in
cancer cell migration and progression is poorly understood.
Most cancer patients die of metastasis instead of the pri-
mary lesion [37, 38]. How to prevent cancer cell migration
has became an area of intense research [39, 40]. Infiltration
of glioma instead of the primary lesion is always the cause
of death for patients diagnosed with malignant gliomas
patients which is highly related to the migration and
invasion malignant cells, is one of the tough questions for
increasing the survival rate. The results of Rac1, Cdc42 and
ERK in U-87 MG cells treated with U0126 indicated that
the inhibition effects of luteolin in migration and invasion
of U-87 MG cells is caused by inhibition of the ERK signal
pathway. Luteolin is beneficial in inhibition of glioma cell
migration and invasion, which may have good therapy
potential in the treatment of brain tumors. A number of
studies have shown that stimulation of luteolin resulted in
inhibition of migration through down regulation of
PDGFR-b, PKC, ERK, Src, PI3 K, and AKT signaling
pathway [41–45]. However, our results showed that
Fig. 6 The inhibitory of migration by luteolin treatment was restored
by MG132 treatment. a Wound healing assay was performed on U-87
MG cells. Luteolin (30 lM) with or without 0.125 lM MG132 were
added to U-87 MG cells. MG132 was added 4 h before counting cells.
Migrated cells were quantified by manual counting. b The above data
were presented the quantification analysis of above wounds healing
quantification. Data were expressed as the mean ± SE from three
independent experiments. *p \ 0.05 compared with luteolin group.
c U-87 MG cells were treated with luteolin (30 lL) for 24 h with or
without 0.125 lM MG132 were added. MG132 was added 4 h before
collecting cells, followed by western blot analysis for Cdc42. GAPDH
was a loading control
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luteolin partially reduced PI3K/AKT activation in U-87
MG and T98G cells. The effects of luteolin inhibitory AKT
activity can vary depending on the cellular context. Inter-
esting, the rapid degradation of Cdc42 was observed by
luteolin treatment, even exogenously constitutive active
Cdc42 also presented at a significantly decreased by lute-
olin. By contrast, we showed that the Cdc42 proteins with
luteolin treatment exhibit increased degradation in a oro-
teasome-dependent pathway, as treatment with the pro-
teasome inhibitor MG132 enhanced Cdc42 protein levels.
Consequently, a novel luteolin-mediated inhibitory of
migration pathway is proposed that luteolin inhibited the
invasion and migration of glioblastoma cells is likely to
inhibite PI3K/AKT activation and facilitate protein deg-
radation of Cdc42 via the proteaosome degradation path-
way. The molecular mechanism underlying this inhibition
needs further investigation.
In conclusion, luteolin is able to disrupt the invasion and
migration of U-87 MG and T98G glioblastoma cells. The
pharmacological mechanism of luteolin that inhibits
migration of glioblastoma cells is likely to inhibite PI3K/
AKT activation and facilitates protein degradation of
Cdc42 via the proteaosome degradation pathway. Our
study suggested that the role of luteolin is a potential anti-
neoplastic agent in preventing migration and invasion, and
provide the well-recognized role of being an effective
chemotherapeutic agent for the treatment of GBMs.
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